CLOs on the Move

Society of Atherosclerosis Imaging and Preventio

www.sai-p.org

 
Society of Atherosclerosis Imaging and Prevention is a Damascus, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Riverside Physician Service

Riverside Physician Service is a Bradenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TrueCore Behavioral Solutions

Tampa, Florida-based TrueCore Behavioral Solutions operates residential facilities for youth who have been ordered by the court into juvenile justice facilities. The company has a 20-year history of providing services to at-risk youth, helping young people discover their true core potential to lead productive and rewarding lives. Today, nearly 2,000 TrueCore professionals and staff in facilities across four states offer vital services and support, including alternative education schools and programs for vocational training, substance abuse recovery, behavioral and mental health, and sexual offender treatment.

CONFIDENT SMILE

CONFIDENT SMILE is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Primary Care and Hope Clinic

The Primary Care and Hope Clinic is a not-for-profit healthcare clinic providing quality, affordable family health services to medically uninsured, underserved, Medicare and Medicaid families in Rutherford and Cannon Counties.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.